LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

2023年8月23日 · Livtencity is a prescription medicine used to treat cytomegalovirus (CMV) infection and disease in adults and children 12 years of age and older weighing at least 77 pounds (35 kg) who have received a transplant, when their infection or disease does not respond to treatment with the medicines ganciclovir, valganciclovir, cidofovir or foscarnet.

LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease...

LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

LIVTENCITY is available as a 200 mg tablet. Recommended dose: 400 mg (two 200 mg tablets) twice daily for both adults and children 12 years of age and older weighing at least 77 pounds (35 kg) No dose adjustments are required for patients with impaired renal function or those with mild or moderate hepatic function* Can be taken with or without food

2021年11月24日讯 / 生物谷 BIOON/ --武田制药（Takeda）近日宣布，美国食品和药物管理局（FDA）已批准 抗病毒药物Livtencity（maribavir，TAK-620），用于移植受者治疗对常规抗病毒疗法难治的（有或无基因型耐药）移植后巨细胞病毒（CMV）感染。 Livtencity具体适用于：接受实体 器官移植 （SOT）或造血 干细胞 移植（HSCT）的成人和儿科患者（年龄≥12岁，体重≥35公斤），治疗对更昔洛韦 [ganciclovir]、缬更昔洛韦 [valganciclovir]、膦甲酸 [foscarnet]、西多 …

2021年12月30日 · 2021年11月24日，美国食品药品监督管理局FDA宣布，批准日本武田（Takeda）制药开发的抗病毒疗法 Livtencity （马利巴韦， maribavir）上市，用于治疗接受造血干细胞移植（HSCT）或实体器官移植（SOT）后成人或12岁以上儿童患者的难治性巨细胞病毒（CMV）感染。 这些患者对已有针对CMV的抗病毒疗法不产生应答。 此前，FDA曾授予本品以突破性疗法认定和优先审评资格，用于治疗对既往疗法耐药或难治的移植患者的CMV感染和疾 …

Livtencity is a prescription medicine used to treat cytomegalovirus (CMV) infection and disease in adults and children 12 years of age and older weighing at least 77 pounds (35 kg) who have received a transplant, when their infection or disease does not respond to treatment with the medicines ganciclovir, valganciclovir, cidofovir or foscarnet.

2025年3月4日 · LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that ...

2023年9月14日 · LIVTENCITY is a prescription medicine used to treat cytomegalovirus (CMV) infection and disease in adults and children 12 years of age and older and weighing at least 77 pounds (35 kg) who have...